Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DSGN 
Design Therapeutics Inc (DSGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: DSGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.67
1 Year Target Price $10.67
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.86% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 534.89M USD | Price to earnings Ratio - | 1Y Target Price 10.67 |
Price to earnings Ratio - | 1Y Target Price 10.67 | ||
Volume (30-day avg) 3 | Beta 1.68 | 52 Weeks Range 2.60 - 9.85 | Updated Date 11/30/2025 |
52 Weeks Range 2.60 - 9.85 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.3367 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.49% | Return on Equity (TTM) -29.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 330662678 | Price to Sales(TTM) 22642.01 |
Enterprise Value 330662678 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56963757 | Shares Floating 26602075 |
Shares Outstanding 56963757 | Shares Floating 26602075 | ||
Percent Insiders 35.97 | Percent Institutions 58.9 |
Upturn AI SWOT
Design Therapeutics Inc
Company Overview
History and Background
Design Therapeutics, Inc. was founded in 2017 and is based in Carlsbad, California. It is a clinical-stage biotechnology company focused on developing gene targeted chimera (GeneTAC) molecules for the treatment of diseases caused by inherited nucleotide repeats.
Core Business Areas
- GeneTAC Platform: Design Therapeutics' core business is the development of its GeneTAC platform. This platform is designed to target the underlying genetic cause of repeat expansion disorders by selectively degrading disease-causing RNA.
- Drug Development: The company is involved in discovering, developing, and commercializing novel therapies for patients with debilitating inherited diseases.
Leadership and Structure
Andres Sirulnik is the CEO. The company's organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Freidreich's Ataxia (FA) Program: Design Therapeutics is developing a GeneTAC molecule to target the FXN gene, which is responsible for Freidreich's Ataxia. There is no current cure for FA. Competitors could be companies developing gene therapies or other novel approaches for FA treatment.
- Myotonic Dystrophy Type 1 (DM1) Program: Design Therapeutics is developing a GeneTAC molecule to target the DMPK gene, which is responsible for Myotonic Dystrophy Type 1. The competitive landscape includes companies developing antisense oligonucleotides, gene therapies, and small molecules for DM1.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high levels of research and development, regulatory scrutiny, and long development timelines. The market for genetic therapies is rapidly growing, with significant investment and increasing regulatory approvals.
Positioning
Design Therapeutics is positioned as a pioneer in the development of GeneTAC therapies for repeat expansion disorders. Its competitive advantage lies in its novel platform and focus on addressing the root cause of genetic diseases.
Total Addressable Market (TAM)
The TAM for repeat expansion disorders is estimated to be billions of dollars. Design Therapeutics is positioned to capture a significant portion of this market if its GeneTAC therapies are successful in clinical trials and receive regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel GeneTAC platform
- Focus on addressing the root cause of genetic diseases
- Strong intellectual property position
- Experienced management team
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited commercial infrastructure
Opportunities
- Expanding the GeneTAC platform to other genetic diseases
- Partnering with larger pharmaceutical companies
- Securing regulatory approvals for its lead programs
- Advancing its pipeline into later-stage clinical trials
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biotechnology companies
- Economic downturn
Competitors and Market Share
Key Competitors
- IONS
- CRSP
- SRPT
Competitive Landscape
Design Therapeutics faces competition from established biotechnology companies. Its GeneTAC platform offers a unique approach, but its success depends on clinical trial results.
Growth Trajectory and Initiatives
Historical Growth: Design Therapeutics' growth is primarily driven by its research and development progress.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing its lead programs into clinical trials and expanding its GeneTAC platform.
Summary
Design Therapeutics is a promising biotech company pioneering GeneTAC therapies for repeat expansion disorders. Its success hinges on clinical trial outcomes and regulatory approvals. The company faces risks typical of early-stage biotechs but has potential for significant growth. It needs to secure more partnerships and financing for long term growth and navigate complex regulatory requirements.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Design Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on estimations and publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Design Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.designtx.com |
Full time employees 55 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.